表紙
市場調查報告書

癌症免疫療法的全球市場:用量、價格、臨床試驗的考察

Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026

出版商 KuicK Research 商品編碼 926418
出版日期 內容資訊 英文 600 Pages
商品交期: 最快1-2個工作天內
價格
癌症免疫療法的全球市場:用量、價格、臨床試驗的考察 Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026
出版日期: 2020年02月01日內容資訊: 英文 600 Pages
簡介

本報告提供全球癌症免疫療法市場相關調查,各免疫療法概要,今後的預測與商業性方面,臨床實驗平台,上市藥,可得性、價格、劑量、銷售額分析的考察,主要企業概要等系統性資訊。

目錄

第1章 癌症免疫療法

  • 癌症免疫療法概要
  • 癌症免疫療法的進步

第2章 癌症免疫療法的種類

  • 特定癌症免疫療法
    • 癌症疫苗
    • 單株抗體
  • 非特異性癌症免疫療法
    • 繼子免疫細胞療法
    • 免疫查核點抑制劑

第3章 癌症免疫療法情勢

  • 對市場有利的趨勢與經濟指標
  • 免疫療法的擴大上應解決的課題

第4章 改變癌症疫苗:免疫療法的展望

  • 癌症疫苗概要
  • 免疫療法的癌症疫苗
  • 癌症疫苗的商業性方面

第5章 單株抗體:免疫療法的新時代

  • 單株抗體的基礎
  • 單株抗體的登場
  • 單株抗體的商業性方面

第6章 T細胞療法的歷史沿革

  • 繼子細胞移植技術
  • 繼子細胞移植的策略
  • 繼子細胞療法的商業性方面

第7章 免疫療法的免疫查核點抑制劑的適應

  • 免疫查核點抑制劑概要
  • 免疫查核點抑制劑的適應症
  • 免疫查核點抑制劑的商業性方面

第8章 癌症免疫療法的免疫調節劑所扮演的角色

  • 免疫調節劑的展望
  • 免疫調節劑的臨床性方面
  • 免疫調節劑的商業性方面

第9章 腫瘤溶解性病毒免疫療法的開發

  • 腫瘤溶解性病毒的概念
  • 腫瘤溶解性病毒潛在的方法
  • 腫瘤溶解性病毒的商業性方面

第10章 細胞激素和癌症免疫療法

  • 細胞激素的基礎
  • 細胞激素的分類
  • 細胞激素的商業性方面

第11章 免疫療法的干擾素

  • 干擾素的可能性
  • 干擾素的分類
  • 干擾素臨床應用

第12章 免疫療法的白細胞介素

  • 白細胞介素的可能性
  • 白細胞介素臨床應用

第13章 免疫療法的顆粒球單球細胞聚落刺激因子(GM-CSF)

  • GM-CSF的可能性
  • GM-CSF臨床應用

第14章 癌症免疫療法的市場概要

  • 目前市場趨勢
  • 癌症免疫療法的經濟方面
  • 癌症免疫療法的成本:各產品

第15章 癌症免疫療法開發平台概要

  • 各藥物類別
  • 各病期
  • 各企業
  • 各標的
  • 患者各種類

第16章 癌症免疫查核點抑制劑 - 可得性、價格、劑量、銷售額分析

  • Keytruda(Pembrolizumab)
  • Yervoy(Ipilimumab)
  • Opdivo(Nivolumab)
  • Tecentriq(Atizolizumab)
  • Bavencio(Avelumab)
  • Imfinzi(Darlumuvab)
  • Libtayo(Cemiplimab)

第17章 癌症單株抗體市場 - 可得性、價格、劑量、銷售額分析

  • Herceptin(Trastuzumab)
  • Avastin(Bevacizumab)
  • MabThera/Rituxan(Rituximab)
  • Erbitux(Cetuximab)
  • Vectibix(Panitumab)
  • Arzerra(Ofatumumab)
  • Gazyva(Obinutuzumab)
  • Perjeta(Pertuzumab)

第18章 雙特異性抗體市場 - 可得性、價格、劑量、銷售額分析

  • Blincyto(Blinatumomab)

第19章 癌症疫苗市場 - 可得性、價格、劑量、銷售額分析

  • Gardasil & Gardasil
  • Cervarix
  • Provenge(Sipuleucel-T)
  • Vaxira(Racotumomab)
  • CreaVax-RCC

第20章 癌症細胞激素藥市場 - 可得性、價格、劑量、銷售額分析

  • Proleukin(Aldeslukin)
  • Intron A(Interferon Alpha-2b)
  • PegIntron(PegInterferon alpha-2b)
  • Sylatron(Peginterferon Alpha-2b)
  • Betaseron(Interferon Beta-1b)
  • Actimmune(Interferon Gamma-1b)
  • Ontak(Denileukin Diftitox)

第21章 腫瘤溶解性病毒市場 - 可得性、價格、劑量、銷售額分析

  • Imlygic

第22章 CAR-T細胞療法 - 可得性、價格、劑量、銷售額分析

  • Kymriah
  • Yescarta

第23章 已上市癌症細胞治療藥

  • T-Lymphocyte Cell Therapy(Immuncell-LC)
  • Zalmoxis
  • APCEDEN For RCC
  • Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

第24章 已上市細胞激素藥

  • Aldesleukin(Proleukin)
  • Denileukin Diftitox(ONTAK)
  • Interferon Alpha(Multiferon)
  • Interferon Alpha-2a(Roferon-A)
  • Interferon Alpha-2a(Veldona)
  • Interferon Alpha-2a Biosimilar(Inferon/Inmutag)
  • Interferon Alpha-2b(Intron)
  • Interferon Alpha-2b Biosimilar(Bioferon)
  • Interferon Alpha-2b Biosimilar(Intalfa)
  • Interferon Alpha-2b Biosimilar
  • Interferon Alpha-2b Biosimilar(ReliFeron)
  • Interferon-Alpha-n3(Alferon N)
  • Interferon-Beta-1b(Feron)
  • Interferon-Gamma(Ogamma)
  • Interleukin-2 Biosimilar(Ilcass)
  • Teceleukin(Imunace)

第25章 已上市癌症疫苗

  • 膀胱癌疫苗(PACIS)
  • 膀胱癌疫苗
  • BV NSCLC
  • 樹突狀細胞疫苗(CreaVax-HCC/CreaVax-PC/CreaVax-RCC)
  • 人類乳突病毒疫苗四價(Gardasil/Silgard)
  • 人類乳突病毒疫苗重組二價(Cervarix)
  • Immuvac/Cadi
  • Immucyst/TheraCys
  • 黑色素瘤疫苗(MVax)
  • 黑色素瘤疫苗(Melacine)
  • Racotumomab (Vaxira)
  • Reniale
  • Sipuleucel-T(Provenge)
  • Tertomotide(LucaVax)
  • Vitespen(Oncophage)

第26章 已上市癌症單株抗體

  • Bevacizumab
  • Trastuzumab Emtansine
  • Trastuzumab Subcutaneous
  • Brentuximab Vedotin
  • Catumaxomab
  • Ipilimumab
  • Nivolumab
  • Pembrolizumab
  • Pertuzumab
  • Rituximab
  • Trastuzumab
  • Gemtuzumab Ozogamicin
  • 其他

第27章 全球癌症免疫療法市場未來展望

第28章 企業簡介

  • Abbvie
  • Advaxis
  • Altor BioScience
  • Amgen
  • Biogen Idec
  • Biogenomics
  • Celldex Therapeutics
  • Dendreon Corporation
  • Eli Lilly
  • Expression Genetics
  • Galena Biopharma
  • Genmab
  • Gilead Sciences
  • GlaxoSmithKline
  • ImmunoCellular Therapeutics
  • ImmunoGen
  • Inovio Pharmaceuticals
  • IRX Therapeutics
  • Merck
  • NeoStem Oncology
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novartis
  • Peregrine Pharmaceuticals
  • Pfizer
  • Philogen
  • Regulon
  • Roche
  • Seattle Genetics
  • ZymoGenetics
目錄

"Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

  • Global Cancer Immunotherapy Market Opportunity: > US$ 200 Billion
  • Cancer Immunotherapy Clinical Trials: > 2300 Drugs In Trials
  • Commercially Available Cancer Immunotherapies: > 120
  • Cancer Vaccines Market Opportunity: > US$ 20 Billion
  • Cancer Monoclonal Antibodies Market Opportunity: > US$ 90 Billion
  • Marketed Cancer Monoclonal Antibodies': > 70 mAbs
  • Sales, Market Opportunity, Dosage & Price Data: 300 Graphs/Charts
  • Clinical Trials Insight By Phase, Company, Patient Segment, Drug Class

The research report “Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” discusses the implications that the recent scientific research and development has brought in context to the ongoing trends and current market size of the cancer immunotherapy at global and regional level. Additionally, the report depicts the nature of the therapies and the structures that are followed by the cancer immunotherapy approach with detailed profiles of the pharmaceutical companies that are the keynote representer of immunotherapy products in the market.

"Cancer Immunotherapy Has Emerged As Next Growth Frontier With US$ 200 Billion In Market Opportunity For Multiple Stake Holders Involved In The Research & Development Of Anti Cancer Therapies"

The immunotherapy defends the normal cells by activating the body's immune system against the cancerous cells. The immunotherapy attractively summons the manipulated body's own natural immune cells and causes the eviction of the cancer cells. The immunotherapy techniques such as T-cell therapy, Immune checkpoint inhibitors, Cancer vaccines, Monoclonal Antibodies and many more have offered the cancer patients with no or less hope and with substantial benefit of meaningful improvements. The growth of the respective market is attributed to the advantage that it provides of being a potential one-time treatment with long and durable response.

Different cancer immunotherapies have been developed and successfully marketed across the globe for various malignancies. They may differ in modality but all of them have some common features due to which they are in high demand among cancer patients. Development of results is apparently rapid than other cancer treatment leading to quick alleviation of clinical symptoms. As a result, more cancer patients want them to improve their medical condition in shorter time.

Improved anti-cancer efficacy is another major benefit of cancer immunotherapies which is not offered by other modalities. Fewer side effects are observed during cancer immunotherapy treatment resulting in higher tolerability and improved quality of life. Relapse prevention and increased progression free survival are also improved resulting in increased demand for cancer immunotherapies. Investigators are trying to decipher more underlying principles of cancer immunotherapies in order to offer better medical care to patients.

The aim with which the cancer immunotherapy approach came into existence was to escalate the process of cancer treatment which largely went unnoticed during usage of traditional technologies. Advanced manipulations in all the therapies of cancer immunotherapy have placed the approach above all the other available therapies for cure of cancer. The ease and the technological performance of the therapies results in long term survival of the cancer patients and a more comfortable after treatment life due to the absence of unwanted chemicals in the body and thus leading to less severe side effects. The approach has enhanced the already existing cancer treatment techniques and has marked itself as an important discovery in the field of oncology.

The strategies that are employed by the immunotherapy approach are playing a very important part in the overall medication for the cancer and that has led to the successful and rapid expansion of the overall immunotherapy market in a very short period of time. The cancer immunotherapy market is driven by the fact that the methodologies working under it have a strong clinical pipeline among which monoclonal antibodies constitutes the most widely accepted immunotherapeutic approach at the global level. The impressive rate at which the market is growing is representing a state of progress that the approach will follow in the near future.

Table of Contents

1. Immunotherapy for Cancer

  • 1.1. Introduction to Cancer Immunotherapy
  • 1.2. Advancement of Cancer Immunotherapy

2. Types of Cancer Immunotherapy

  • 2.1. Specific Cancer Immunotherapy
    • 2.1.1. Cancer Vaccines
    • 2.1.2. Monoclonal Antibodies
  • 2.2. Non-Specific Cancer Immunotherapy
    • 2.2.1. Adoptive Cell Transfer Immunotherapy
    • 2.2.2. Immune Checkpoint Inhibitors

3. Dynamics of Global Cancer Immunotherapy Landscape

  • 3.1. Favorable Developmental & Commercialization Parameters
  • 3.2. Issues to be Resolved in Expansion of Immunotherapy Horizon

4. Cancer Vaccines: Transforming The Immunotherapy Landscape

  • 4.1. Prologue of Cancer Vaccines
  • 4.2. Cancer Vaccines in Immunotherapy
  • 4.3. Commercialization of Cancer Vaccines

5. Monoclonal Antibodies: New Era of Immunotherapy

  • 5.1. Rudiments of Monoclonal Antibodies
  • 5.2. Advents of Monoclonal Antibodies
  • 5.3. Commercial Aspects of Monoclonal Antibodies

6. Trails of T-Cell Therapies

  • 6.1. Adoptive Cell Transfer Technology
  • 6.2. Strategies of Adoptive Cell Transfer
  • 6.3. Commercial Aspects of Adoptive Cell Therapy

7. Application of Immune Checkpoint Inhibitors in Immunotherapy

  • 7.1. Prelude to Immune Checkpoint Inhibitors
  • 7.2. Implications of Immunecheck Point Inhibitors
  • 7.3. Commercial Aspects of Immune Checkpoint Inhibitors

8. Role of Immunomodulators in Cancer Immunotherapy

  • 8.1. Perspective of Immunomodulators
  • 8.2. Clinical Aspects of Immunomodulators
  • 8.3. Commercial Aspects of Immunomodulators

9. Development of Oncolytic Viral Immunotherapy

  • 9.1. Concept to Oncolytic Viruses
  • 9.2. Potential Approaches of Oncolytic Viruses
  • 9.3. Commercial Aspects of Oncolytic Viruses

10. Cytokines & Cancer Immunotherapy

  • 10.1. Fundamentals of Cytokines
  • 10.2. Classification of Cytokines
  • 10.3. Commercial Aspects of Cytokines

11. Interferons in Immunotherapy

  • 11.1. Potentials of Interferons
  • 11.2. Classification of Interferons
  • 11.3. Clinical Applications of Interferons

12. Interleukins in Immunotherapy

  • 12.1. Potentials of Interleukins
  • 12.2. Clinical Applications of Interleukins

13. GM-CSF in Immunotherapy

  • 13.1. Potentials of GM-CSF
  • 13.2. Clinical Applications of GM-CSF

14. Market Aspects of Cancer Immunotherapy

  • 14.1. Current Market Trends
  • 14.2. Economic Aspects of Cancer Immunotherapy
  • 14.3. Cancer Immunotherapy Cost by Product

15. Cancer Immunotherapy Pipeline Overview

  • 15.1. By Drug Class
  • 15.2. By Phase
  • 15.3. By Company
  • 15.4. By Target
  • 15.5. By Patient Segment

16. Cancer Immune Check Point Inhibitors - Availability, Price, Dosage & Sales Analysis

  • 16.1. Keytruda (Pembrolizumab)
  • 16.2. Yervoy (Ipilimumab)
  • 16.3. Opdivo (Nivolumab)
  • 16.4. Tecentriq (Atizolizumab)
  • 16.5. Bavencio (Avelumab)
  • 16.6. Imfinzi (Darlumuvab)
  • 16.7. Libtayo (Cemiplimab)

17. Cancer Monclonal Antibody Market - Availability, Price, Dosage & Sales Analysis

  • 17.1. Herceptin (Trastuzumab)
  • 17.2. Avastin (Bevacizumab)
  • 17.3. MabThera/Rituxan (Rituximab)
  • 17.4. Erbitux (Cetuximab)
  • 17.5. Vectibix (Panitumab)
  • 17.6. Arzerra (Ofatumumab)
  • 17.7. Gazyva (Obinutuzumab)
  • 17.8. Perjeta (Pertuzumab)

18. Bispecific Antibody Market - Availability, Price, Dosage & Sales Analysis

  • 18.1. Blincyto (Blinatumomab)

19. Cancer Vaccine Market - Availability, Price, Dosage & Sales Analysis

  • 19.1. Gardasil & Gardasil 9
  • 19.2. Cervarix
  • 19.3. Provenge (Sipuleucel - T)
  • 19.4. Vaxira (Racotumomab)
  • 19.5. CreaVax-RCC

20. Cancer Cytokines Drugs Market - Availability, Price, Dosage & Sales Analysis

  • 20.1. Proleukin (Aldeslukin)
  • 20.2. Intron A (Interferon Alpha-2b)
  • 20.3. PegIntron (PegInterferon alpha-2b)
  • 20.4. Sylatron (Peginterferon Alpha-2b)
  • 20.5. Betaseron (Interferon Beta-1b)
  • 20.6. Actimmune (Interferon Gamma-1b)
  • 20.7. Ontak (Denileukin Diftitox)

21. Oncolytic Virus Market - Availability, Dosage, & Price Analysis

  • 21.1. Imlygic

22. CAR-T Cell Therapy - Availability, Dosage, Price & Sales Analysis

  • 22.1. Kymriah
  • 22.2. Yescarta

23. Marketed Cancer Cell Therapies Drugs

  • 23.1. T-Lymphocyte Cell Therapy(Immuncell-LC®)
  • 23.2. Zalmoxis
  • 23.3. APCEDEN For RCC
  • 23.4. Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

24. Marketed Cancer Cytokines Drugs

  • 24.1. Aldesleukin (Proleukin®)
  • 24.2. Denileukin Diftitox (ONTAK®)
  • 24.3. Interferon Alpha (Multiferon®)
  • 24.4. Interferon Alpha-2a (Roferon-A®)
  • 24.5. Interferon Alpha-2a (Veldona®)
  • 24.6. Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)
  • 24.7. Interferon Alpha-2b(Intron® A)
  • 24.8. Interferon Alpha-2b Biosimilar(Bioferon™)
  • 24.9. Interferon Alpha-2b Biosimilar (Intalfa®)
  • 24.10. Interferon Alpha-2b Biosimilar
  • 24.11. Interferon Alpha-2b Biosimilar (ReliFeron®)
  • 24.12. Interferon-Alpha-n3 (Alferon N®)
  • 24.13. Interferon-Beta-1b (Feron®)
  • 24.14. Interferon-Gamma (Ogamma®)
  • 24.15. Interleukin-2 Biosimilar (Ilcass)
  • 24.16. Teceleukin (Imunace™)

25. Marketed Cancer Vaccines

  • 25.1. Bladder Cancer Vaccine (PACIS®)
  • 25.2. Bladder Cancer Vaccine
  • 25.3. BV NSCLC 001
  • 25.4. Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)
  • 25.5. Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)
  • 25.6. Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
  • 25.7. Immuvac / Cadi 05
  • 25.8. Immucyst / TheraCys
  • 25.9. Melanoma Vaccine (MVax®)
  • 25.10. Melanoma Vaccine (Melacine®)
  • 25.11. Racotumomab (Vaxira®)
  • 25.12. Reniale
  • 25.13. Sipuleucel-T (Provenge®)
  • 25.14. Tertomotide (LucaVax)
  • 25.15. Vitespen (Oncophage®)

26. Marketed Cancer Monoclonal Antibodies

  • 26.1. Bevacizumab
  • 26.2. Trastuzumab Emtansine
  • 26.3. Trastuzumab Subcutaneous
  • 26.4. Brentuximab Vedotin
  • 26.5. Catumaxomab
  • 26.6. Ipilimumab
  • 26.7. Nivolumab
  • 26.8. Pembrolizumab
  • 26.9. Pertuzumab
  • 26.10. Rituximab
  • 26.11. Trastuzumab
  • 26.12. Gemtuzumab Ozogamicin
  • 26.13. Others

27. Global Cancer Immunotherapy Market Future Prospects

28. Competitive Landscape

  • 28.1. Abbvie
  • 28.2. Advaxis
  • 28.3. Altor BioScience
  • 28.4. Amgen
  • 28.5. Biogen Idec
  • 28.6. Biogenomics
  • 28.7. Celldex Therapeutics
  • 28.8. Dendreon Corporation
  • 28.9. Eli Lilly
  • 28.10. Expression Genetics
  • 28.11. Galena Biopharma
  • 28.12. Genmab
  • 28.13. Gilead Sciences
  • 28.14. GlaxoSmithKline
  • 28.15. ImmunoCellular Therapeutics
  • 28.16. ImmunoGen
  • 28.17. Inovio Pharmaceuticals
  • 28.18. IRX Therapeutics
  • 28.19. Merck
  • 28.20. NeoStem Oncology
  • 28.21. NewLink Genetics
  • 28.22. Northwest Biotherapeutics
  • 28.23. Novartis
  • 28.24. Peregrine Pharmaceuticals
  • 28.25. Pfizer
  • 28.26. Philogen
  • 28.27. Regulon
  • 28.28. Roche
  • 28.29. Seattle Genetics
  • 28.30. ZymoGenetics

List of Figures

  • Figure 1-1: Evolutionary Trails of Cancer Immunotherapy
  • Figure 1-2: Layout of Necessity of Cancer Immunotherapies for Cancer Treatment
  • Figure 1-3: Potential Benefits of Cancer Immunotherapies
  • Figure 2-1: Classification of Cancer Immunotherapies
  • Figure 2-2: Categorization of Specific Immunotherapy
  • Figure 2-3: Non-Specific Cancer Immunotherapies
  • Figure 3-1: Favorable Cancer Immunotherapy Market Parameters
  • Figure 3-2: Cancer Immunotherapy Commercialization Challenges
  • Figure 4-1: Categorization & Function of Cancer Vaccines
  • Figure 4-2: Mechanism of the Cancer Vaccine towards Tumor Eradication
  • Figure 4-3: Global - Cancer Vaccines Market (US$ Billion), 2018-2026
  • Figure 5-1: Process of Manufacturing of Monoclonal Antibody
  • Figure 5-2: Principles of Monoclonal Antibodies
  • Figure 5-3: Evolution of Monoclonal Antibody over Generations
  • Figure 5-4: Classification of Monoclonal Antibodies
  • Figure 5-5: Representation of Mechanism of Alemtuzumab
  • Figure 5-6: Representation of Mechanism of Ibritumomab Tiuxetan
  • Figure 5-7: Representation of Mechanism of Blinatumomab
  • Figure 5-8: Global - Market for Cancer Monoclonal Antibodies (US$ Billion), 2018-2026
  • Figure 6-1: Benefit of Adoptive Cell Transfer Immunotherapy
  • Figure 6-2: Systematic Representation of Adoptive T-Cell Therapies
  • Figure 6-3: Three Adoptive Cell Transfer Strategies for Cancer Immunotherapy
  • Figure 6-4: Tumor-Infiltrating Lymphocytes in Adoptive Cell Transfer
  • Figure 6-5: Mechanism of CAR Modified T-Cells
  • Figure 6-6: Genetically Engineered TCR for Cancer Immunotherapy
  • Figure 6-7: Global - Predictive Market of CAR T-Cell Therapeutics (US$ Million), 2018-2026
  • Figure 7-1: Benefits of Immune Checkpoint Inhibitors
  • Figure 7-2: Implication of Adaptive Immune Resistance Mechanism
  • Figure 7-3: Mechanism of Ipilimumab
  • Figure 7-4: Layout of Mechanism of Nivolumab
  • Figure 7-5: Mechanism of Pembrolizumab
  • Figure 7-6: Global - Immune Check Point Inhibitors Market (US$ Billion), 2018-2026
  • Figure 8-1: Functions of Immunomodulators
  • Figure 8-2: Benefits of Immunomodulators
  • Figure 8-3: Layout of the Challenges of Immunomodulators
  • Figure 8-4: Properties of Thalidomide
  • Figure 8-5: Mechanism of Lenalidomide In Vivo
  • Figure 8-6: Mechanism of Lenalidomide in Vitro
  • Figure 8-7: Mechanism of Pomalidomide
  • Figure 8-8: Global - Immunomodulators Market for All Indications (US$ Billion), 2018-2026
  • Figure 9-1: Demonstration of Categorization of Oncolytic Viruses
  • Figure 9-2: Potential Advantages of Oncolytic Viruses over Conventional Therapies
  • Figure 9-3: Global - Predicted Market Share of Oncolytic Viral Therapies (US$ Million), 2018-2026
  • Figure 10-1: Layout of Functions Performed by Cytokine
  • Figure 10-2: Benefits of Cytokines in Cancer Immunotherapy
  • Figure 10-3: Classification of Cytokine Receptor Family
  • Figure 10-4: Percentage Share of the Cancer Immunotherapies by the Technology
  • Figure 11-1: Layout of Functions of Interferon
  • Figure 11-2: Classification of Interferons on the Basis of Types of Genes
  • Figure 11-3: General Mechanism of Interferons
  • Figure 11-4: Mechanism of Interferon Alfa-n3
  • Figure 11-5: Aspects of Peginterferon Alfa-2a
  • Figure 11-6: Applications of Interferon Beta 1a
  • Figure 11-7: Potentials of Interferon Alfa-2b
  • Figure 12-1: Functions of Interleukin
  • Figure 12-2: Potentials of Interleukins in Cancer Immunotherapy
  • Figure 12-3: Clinical Potentials of Proleukin
  • Figure 12-4: Clinical Potentials of Denileukin Diftitox
  • Figure 13-1: Potential Applications of GM-CSF
  • Figure 13-2: Mechanism of Sargramostim
  • Figure 14-1: Global - Cancer Immunotherapeutic Market (US$ Billion), 2018-2026
  • Figure 14-2: Expected Cancer Treatment Cost (US$ Billion), 2016-2022
  • Figure 14-3: Comparative Analysis of Available Cancer Treatments
  • Figure 14-4: Major Approved Immunotherapeutic Drugs
  • Figure 14-5: Annual per Patient Drug Expenditure of Immunotherapy
  • Figure 15-1: Global - Cancer Vaccine Clinical Pipeline by Phase (%), 2020 - 2026
  • Figure 15-2: Global - Cancer Vaccine Clinical Pipeline by Phase (Number), 2020 -2026
  • Figure 15-3: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2020 -2026
  • Figure 15-4: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2020 -2026
  • Figure 15-5: Global - Cancer Cell Therapies Clinical Pipeline by Phase (%), 2020 -2026
  • Figure 15-6: Global - Cancer Cell Therapies Clinical Pipeline by Phase (Number), 2020 -2026
  • Figure 15-7: Global - Cancer Immunomodulators Clinical Pipeline by Phase (%), 2020 - 2026
  • Figure 15-8: Global - Cancer Immunomodulators Clinical Pipeline By Phase (Number), 2020 - 2026
  • Figure 15-9: Global - Cancer Immunotherapy Clinical Pipeline by Phase (Number), 2020 -2026
  • Figure 15-10: Global - Cancer Immunotherapy Clinical Pipeline by Company (Number), 2020 -2026
  • Figure 15-11: Global - Cancer Immunotherapy Clinical Pipeline by Target (Number), 2020 -2026
  • Figure 15-12: Global - Cancer Immunotherapy Clinical Pipeline by Patient Segment (Number), 2020 -2026
  • Figure 16-1: Keytruda - Patent Expiration Year by Region
  • Figure 16-2: Keytruda - Price for 4ml & 8ml Supply & Price per ml of Intravenous Injection (US$), January'2020
  • Figure 16-3: Keytruda - Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks), January'2020
  • Figure 16-4: Keytruda - Cost of Single and Full Treatment using Powder of Injection (US$), January'2020
  • Figure 16-5: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$), January'2020
  • Figure 16-6: Keytruda - Annual Sales Value (US$ Billion), 2016, 2017 & 2018
  • Figure 16-7: Keytruda - Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
  • Figure 16-8: Yervoy - US & Europe Exclusivity Expiration Year
  • Figure 16-9: Yervoy - Price for 10ml Supply & Price per ml 5mg/ml Intravenous Injection (US$), January'2020
  • Figure 16-10: Yervoy - Price for 40ml Supply & Price per ml 5mg/ml Intravenous Injection (US$), January'2020
  • Figure 16-11: Yervoy - Duration of Single Treatment Cycle & Full Treatment of Metastatic Melanoma (Weeks), January'2020
  • Figure 16-12: Yervoy - Average Cost of Single Treatment Cycle & Full Treatment of Metastatic Melanoma (US$), January'2020
  • Figure 16-13: Yervoy - Average Cost of Single Treatment Cycle, Initial Year & Remaining Years for Management of Metastatic Melanoma (US$), January'2020
  • Figure 16-14: Yervoy - Duration of Single Treatment Cycle & Full Treatment in Combinational Therapy (Weeks), January'2020
  • Figure 16-15: Yervoy - Average Cost of Single Treatment Cycle & Full Treatment in Combinational Therapy (US$), January'2020
  • Figure 16-16: Yervoy - Annual Sales Value (US$ Billion), 2016-2018
  • Figure 16-17: Yervoy - Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
  • Figure 16-18: US - Yervoy Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
  • Figure 16-19: Yervoy - US v/s Rest of World Sales Share (%), Q1-Q3, 2019
  • Figure 16-20: Opdivo - Patent Expiration Year by Region
  • Figure 16-21: Opdivo - Price for 4ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$), January'2020
  • Figure 16-22: Opdivo - Price for 10 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$), January'2020
  • Figure 16-23: Opdivo - Price for 20 ml Supply & Price per ml of 10mg/ml Intravenous Injection (US$), January'2020
  • Figure 16-24: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), January'2020
  • Figure 16-25: Opdivo Combination - Dose for Management of Melanoma & Renal Cell Carcinoma (mg/3 Weeks)), January'2020
  • Figure 16-26: Opdivo - Annual Sales Value (US$ Billion), 2016 - 2018
  • Figure 16-27: Opdivo - Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
  • Figure 16-28: US - Opdivo - Quarterly Sales Value (US$ Billion), Q1-Q3, 2019
  • Figure 16-29: Opdivo - 9 Month Sales Share of US & Rest of World (%), Q1-Q3, 2019
  • Figure 16-30: Tecentriq - Price for 14ml Supply & Price per ml of 840mg/14ml Intravenous Injection (US$), January'2020
  • Figure 16-31: Tecentriq - Price for 20ml Supply & Price per ml of 1200mg/20ml Intravenous Injection (US$), January'2020
  • Figure 16-32: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 840mg/2 Week Dose (US$), January'2020
  • Figure 16-33: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1200mg/3 Week Dose (US$), January'2020
  • Figure 16-34: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1680mg/4 Week Dose (US$), January'2020
  • Figure 16-35: Tecentriq - Annual Sales Value (US$/CHF Million), 2017 & 2018
  • Figure 16-36: Tecentriq - Quarterly Sales Value (US$ Million), Q1-Q3, 2019
  • Figure 16-37: Tecentriq - Quarterly Sales Value (US$ Million), 2018
  • Figure 16-38: Tecentriq - Sales Value of US v/s ROW (US$ Billion), Q1-Q3, 2019
  • Figure 16-39: Tecentriq - 9 Month Sales Share by Region (%), Q1-Q3, 2019
  • Figure 16-40: Bavencio - Price for 10ml Supply & Price per ml of 20mg/ml Intravenous Injection (US$), January'2020
  • Figure 16-41: Bavencio - Average Cost of Single Treatment Cycle & Annual Treatment (US$), January'2020
  • Figure 16-42: Bavencio - Annual Sales Value (US$/EUR Million), 2017 & 2018
  • Figure 16-43: Bavencio - Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
  • Figure 16-44: Imfinzi - FDA Approval & Patent Expiration Year
  • Figure 16-45: Imfinzi - Price for a Supply of 2.4ml & Price per ml of Solution for Injection (US$), January'2020
  • Figure 16-46: Imfinzi - Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), January'2020
  • Figure 16-47: Imfinzi - Average Cost of Single Treatment Cycle & Full Treatment of NSCLC (US$), January'2020
  • Figure 16-48: Imfinzi - Annual Sales Value (US$ Million), 2017 & 2018
  • Figure 16-49: Imfinzi - Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
  • Figure 16-50: Libtayo - Price for a Supply of 7ml & Price per ml of Solution for Injection (US$), January'2020
  • Figure 16-51: Libtayo - Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2020
  • Figure 16-52: Libtayo - Quarterly Sales Value (US$ Million), Q1-Q3, 2019
  • Figure 16-53: US - Libtayo Quarterly Sales Value (US$ Million), Q1-Q3, 2019
  • Figure 16-54: Libtayo - 9 Month Sales Share - US v/s Rest of World (%), Q1-Q3, 2019
  • Figure 16-55: Libtayo - 9 Month Sales of US v/s Rest of World (US$ Million), Q1-Q3, 2019
  • Figure 17-1: Herceptin - Approval Year by Cancer Type
  • Figure 17-2: Herceptin - Price for a Supply of 10 and Price for Single 150mg Powder for Injection (US$), January'2020
  • Figure 17-3: Herceptin - Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg), January'2020
  • Figure 17-4: Herceptin - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Breast Cancer (US$), January'2020
  • Figure 17-5: Herceptin - Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg), January'2020
  • Figure 17-6: Herceptin - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US$), January'2020
  • Figure 17-7: Herceptin - Annual Sales Value (US$/CHF Billion), 2017 & 2018
  • Figure 17-8: Herceptin - Quarterly Sales Value (US$/CHF Billion), Q1-Q4, 2018
  • Figure 17-9: Herceptin - Quarterly Sales Value (US$/CHF Billion), Q1-Q3, 2019
  • Figure 17-10: US - Herceptin - Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
  • Figure 17-11: Herceptin - Sales Value - US v/s ROW (US$ Billion), 2018
  • Figure 17-12: Herceptin -Sales Share by Region (%), 2018
  • Figure 17-13: Avastin - Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$), January'2020
  • Figure 17-14: Avastin - Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$), January'2020
  • Figure 17-15: Avastin - Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), January'2020
  • Figure 17-16: Avastin - Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), January'2020
  • Figure 17-17: Avastin - Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks), January'2020
  • Figure 17-18: Avastin - Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), January'2020
  • Figure 17-19: Avastin - Annual Sales Value (US$/CHF Billion), 2017 & 2018
  • Figure 17-20: Avastin - Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
  • Figure 17-21: US - Avastin - Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
  • Figure 17-22: Avastin - 9 Month Sales Share by Region (US$ Billion), Q1-Q3, 2019
  • Figure 17-23: Avastin - 9 Month Sales Share of US & Rest of World (%), Q1-Q3, 2019
  • Figure 17-24: Rituxan - Price for a Supply of 10 ml & Price per ml of Solution for Injection (US$), January'2020
  • Figure 17-25: Rituxan - Price for a Supply of 50 ml & Price per ml of Solution for Injection (US$), January'2020
  • Figure 17-26: Rituxan - Price for a Supply of 100 ml & Price per ml of Solution for Injection (US$), January'2020
  • Figure 17-27: Rituxan - Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL (US$), January'2020
  • Figure 17-28: Rituxan - Average Cost for Single Dose & Cost of Full Maintenance Phase for Non-Progressing CD20+ B-Cell NHL (US$), January'2020
  • Figure 17-29: Rituxan - Annual Sales Value (US$/CHF Billion), 2017 & 2018
  • Figure 17-30: Rituxan - Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 & 2019
  • Figure 17-31: US - Rituxan - Quarterly Sales Value (US$ Billion), Q1-Q3, 2019
  • Figure 17-32: Avastin - 9 Month Sales Share of US & Rest of World (%), Q1-Q3, 2019
  • Figure 17-33: Rituxan - 9 Month Sales Share by Region (CHF/US$ Billion)), Q1-Q3, 2019
  • Figure 17-34: Rituxan - 9 Month Sales Share by Region (%), Q1-Q3, 2019
  • Figure 17-35: Erbitux - Approval Year by Cancer Type
  • Figure 17-36: Erbitux - Price for a Supply of 50 ml & Price per ml of Intravenous Solution (US$), January'2020
  • Figure 17-37: Erbitux - Price for a Supply of 100 ml & Price per ml of Intravenous Solution (US$), January'2020
  • Figure 17-38: Erbitux - Initial & Maintenance Dose for Colorectal, Head & Neck Cancer Treatment (mg/ m2), January'2020
  • Figure 17-39: Erbitux - Average Cost of Initial Dose, Maintenance Dose & Cost of Annual Treatment (US$), January'2020
  • Figure 17-40: Erbitux - Annual Sales Value (US$ Million), 2016 - 2018
  • Figure 17-41: US - Erbitux Sales Value (US$ Million), 2017 & 2018
  • Figure 17-42: Erbitux - Sales Share US v/s Rest of World (%), 2018
  • Figure 17-43: Erbitux - Quarterly Sales Value (US$ Million), Q1-Q3, 2017 & 2018
  • Figure 17-44: Vectibix - FDA Approval & Patent Expiration Year
  • Figure 17-45: Vectibix - Price for a Supply of 5 ml & Price per ml of Intravenous Solution (US$), January'2020
  • Figure 17-46: Vectibix - Price for a Supply of 20 ml & Price per ml of Intravenous Solution (US$), January'2020
  • Figure 17-47: Vectibix - Cost of Single Treatment Cycle & Annual Treatment Cost for Colorectal Cancer (US$), January'2020
  • Figure 17-48: Vectibix - Annual Sales Value (US$ Million), 2015 - 2018
  • Figure 17-49: Vectibix - Sales Share US v/s Rest of World (%), 2018
  • Figure 17-50: Vectibix - Quarterly Sales Value (US$ Million), Q1 - Q3, 2018 & 2019
  • Figure 17-51: Vectibix - 9 Month Sales Share US v/s Rest of World (%), Q1 - Q3, 2019
  • Figure 17-52: Arzerra - Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), January'2020
  • Figure 17-53: Arzerra - Price for a Supply of 50 ml & Price per ml of Intravenous Solution (US$), January'2020
  • Figure 17-54: Arzerra - Initial & Maintenance Dose for Previously Untreated CLL (mg), January'2020
  • Figure 17-55: Arzerra - Minimum & Maximum Treatment Duration for Previously Untreated CLL (Weeks), January'2020
  • Figure 17-56: Arzerra - Minimum & Maximum Treatment Cost for Previously Untreated CLL (US$), January'2020
  • Figure 17-57: Arzerra - Initial & Maintenance Dose for Relapsed CLL (mg), January'2020
  • Figure 17-58: Arzerra - Minimum & Maximum Treatment Cost for Relapsed CLL (US$), January'2020
  • Figure 17-59: Arzerra - Initial & Maintenance Dose for Refractory CLL (mg), January'2020
  • Figure 17-60: Arzerra - Treatment Duration for Refractory CLL (Weeks), January'2020
  • Figure 17-61: Arzerra - Minimum & Maximum Treatment Cost for Refractory CLL (US$), January'2020
  • Figure 17-62: Gazyva - Approval Year by Cancer Type
  • Figure 17-63: Gazyva - Price for 40ml Supply & Price per ml of Intravenous Solution (US$), January'2020
  • Figure 17-64: Gazyva - Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg), January'2020
  • Figure 17-65: Gazyva - Duration of Single Treatment Cycle & Full Treatment of CLL (Week), January'2020
  • Figure 17-66: Gazyva - Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US$), January'2020
  • Figure 17-67: Gazyva - Minimum & Maximum Duration for Follicular Lymphoma Treatment (Week), January'2020
  • Figure 17-68: Gazyva - Minimum & Maximum Treatment Cost of Follicular Lymphoma (US$), January'2020
  • Figure 17-69: Gazyva - Duration of Single Treatment Cycle & Full Treatment Using Monotherapy (Months), January'2020
  • Figure 17-70: Gazyva - Cost of Single Treatment Cycle & Full Treatment using Monotherapy (US$), January'2020
  • Figure 17-71: Gazyva - Annual Sales Value (US$/CHF Million), 2016 - 2018
  • Figure 17-72: Gazyva - Quarterly Sales Value (US$/CHF Million), 2018
  • Figure 17-73: Gazyva - Quarterly Sales Value (US$/CHF Million), Q1-Q3, 2019
  • Figure 17-74: US - Gazyva - Quarterly Sales Value (US$ Million), Q1-Q3, 2019
  • Figure 17-75: Gazyva - 9 Month Sales Share by Region (CHF/US$ Million), Q1-Q3, 2019
  • Figure 17-76: Gazyva - 9 Month Sales Share by Region (%), Q1-Q3, 2019
  • Figure 17-77: Perjeta - Approval Year by Cancer Type
  • Figure 17-78: Perjeta - Patent Expiration Year - US & Europe
  • Figure 17-79: Perjeta - Price for a Supply of 10 ml and Price per ml of Intravenous Solution (US$), January'2020
  • Figure 17-80: Perjeta - Initial & Maintenance Dose for Breast Cancer Treatment (mg/ 3 weeks), January'2020
  • Figure 17-81: Perjeta - Minimum & Maximum Treatment Cost for Breast Cancer (US$), January'2020
  • Figure 17-82: Perjeta - Minimum & Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$), January'2020
  • Figure 17-83: Perjeta - Annual Sales Value (US$/CHF Billion), 2016 - 2018
  • Figure 17-84: Perjeta - Quarterly Sales Value (US$/CHF Million), 2018
  • Figure 17-85: Perjeta - Quarterly Sales Value (US$/CHF Million), Q1-Q3, 2019
  • Figure 17-86: US - Perjeta - Quarterly Sales Value (US$ Million), Q1-Q3, 2019
  • Figure 17-87: Perjeta - Sales Value by Region (US$/CHF Million), Q1 - Q3, 2019
  • Figure 17-88: Perjeta - Sales Value by Region, Q1 - Q3, 2019
  • Figure 18-1: Blincyto - Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, January'2020
  • Figure 18-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , January'2020
  • Figure 18-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US$), January'2020
  • Figure 18-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, January'2020
  • Figure 18-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), January'2020
  • Figure 18-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), January'2020
  • Figure 18-7: Blincyto - Cost of Different Treatment Phases & Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), January'2020
  • Figure 18-8: Blincyto - Sales Value (US$ Million), 2015 - 2018
  • Figure 18-9: US - Blincyto Sales Value (US$ Million), 2016 - 2018
  • Figure 18-10: Blincyto - Quarterly Sales Value (US$ Million), 2018
  • Figure 18-11: Blincyto - US v/s Rest of World Share in Sales Value (%), 2018
  • Figure 18-12: Blincyto - Quarterly Sales Value (US$ Million), Q1 - Q3, 2018 & 2019
  • Figure 18-13: Blincyto - US & Rest of World Sales Value (US$ Million), Q1 - Q3, 2019
  • Figure 18-14: Blincyto - US v/s ROW Share in 9 Month Sales Value (%), 2019
  • Figure 19-1: Gardasil & Gardasil 9 - FDA Approval Year
  • Figure 19-2: Gardasil - Patent Expiration Year of US & Europe
  • Figure 19-3: Gardasil 9 - US & Europe Patent Expiration Year
  • Figure 19-4: Gardasil - Price for 0.5ml Supply & Price per ml of Intravenous Suspension (US$), January'2020
  • Figure 19-5: Gardasil - Price for 3ml Supply & Price per ml of Intravenous Suspension (US$), January'2020
  • Figure 19-6: Gardasil - Price for 5ml Supply & Price per ml of Intravenous Suspension (US$), January'2020
  • Figure 19-7: Gardasil 9 - Price for 5ml Supply & Price per ml of Intravenous Suspension (US$), January'2020
  • Figure 19-8: Gardasil - Cost of Single Dose & Cost of Full Course (US$), January'2020
  • Figure 19-9: Gardasil 9 - Cost of Single Dose & Cost of Full Course (US$), January'2020
  • Figure 19-10: Gardasil & Gardasil 9 - Annual Sales Value (US$ Million), 2016, 2017 & 2018
  • Figure 19-11: Gardasil and Gardasil 9 - Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
  • Figure 19-12: Cervarix - US & Europe Patent Expiration Year
  • Figure 19-13: Cervarix - Cost of Single Dose & Cost of Full Course (US$/GBP Million), January'2020
  • Figure 19-14: Cervarix - Annual Sales Value (US$/GBP Million), 2016 - 2018
  • Figure 19-15: Cervarix - Sales Share Europe v/s Rest of World (%), 2018
  • Figure 19-16: Cervarix - Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
  • Figure 19-17: Cervarix - Europe v/s Rest of World Sales Share (%), Q1-Q3, 2019
  • Figure 19-18: Provenge - Price for 250 ml Supply & Price per ml of Intravenous Suspension (US$), January'2020
  • Figure 19-19: Provenge - Cost of Single Treatment Cycle & Cost of Full Treatment (US$), January'2020
  • Figure 19-20: Vaxira - Cost for Single Injection & Single Dose (US$), January'2020
  • Figure 19-21: Vaxira - Number of Doses in Induction & Maintenance Phase, January'2020
  • Figure 19-22: Vaxira - Dose Interval in Induction & Maintenance Phase (Week), January'2020
  • Figure 19-23: Vaxira - Duration of Induction & Maintenance Phase (Weeks), January'2020
  • Figure 19-24: Vaxira - Cost of Induction & Maintenance Phase (US$), January'2020
  • Figure 19-25: CreaVax-RCC - Duration of Single Cycle & Full Treatment (Weeks), January'2020
  • Figure 20-1: Proleukin - Duration of Treatment by Phases (Hours), January'2020
  • Figure 20-2: Proleukin - Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), January'2020
  • Figure 20-3: Proleukin - Number of Doses for Metastatic Renal Cell Carcinoma & Melanoma, January'2020
  • Figure 20-4: Proleukin - Average Cost For Treatment of Metastatic RCC & Melanoma, January'2020
  • Figure 20-5: Intron A - Price for a Supply of 10, 18 & 50 Million IU Powder for Injection (US$), January'2020
  • Figure 20-6: Intron A - Price for a Supply of 6 & 10 Million IU/ml Intravenous Solution (US$), January'2020
  • Figure 20-7: Intron A - Average Cost of Single Treatment Cycle for Hairy Cell Leukemia using Powder & Solution for Injection (US$), January'2020
  • Figure 20-8: Intron A - Average Cost of Full Treatment for Course Hairy Cell Leukemia using Powder & Solution for Injection (US$), January'2020
  • Figure 20-9: Intron A - Dose for Induction & Maintenance Phase for Malignant Melanoma Treatment (Million IU/m2), January'2020
  • Figure 20-10: Intron A - Duration of Induction & Maintenance Phase for Malignant Melanoma Treatment (Weeks), January'2020
  • Figure 20-11: Intron A - Duration of Single Treatment Cycle & Full Treatment of Follicular Lymphoma (Weeks), January'2020
  • Figure 20-12: PegIntron - Patent Expiration Year by Region
  • Figure 20-13: PegIntron - Price for 4 Powder Supply & Price Per Unit of 120mg Powder for Injection (US$), January'2020
  • Figure 20-14: PegIntron Monotherapy - Dose by Weight of Patient (mcg), January'2020
  • Figure 20-15: PegIntron Monotherapy - Reduced Dose by Weight of Patient (mcg), January'2020
  • Figure 20-16: Pegintron Combination - Duration of Treatment by Genotype (Weeks), January'2020
  • Figure 20-17: Sylatron - Price for 4 Powder Supply & Price per Unit of 120mg Powder for Injection (US$), January'2020
  • Figure 20-18: Sylatron - Initial & Maintenance Dose (mcg/Kg/Week), January'2020
  • Figure 20-19: Sylatron - Duration of Initial Phase, Maintenance Phase & Full Treatment (Weeks), January'2020
  • Figure 20-20: Sylatron - Average Cost of Single Initial Dose & Full Initial Phase (US$), January'2020
  • Figure 20-21: Sylatron - Average Cost of Single Maintenence Dose, Annual Maintenance Cost & Full Maintenance Phase (US$), January'2020
  • Figure 20-22: Betaseron - Price for 14 Powder Supply & Price per Unit of 0.3mg Powder for Injection (US$), January'2020
  • Figure 20-23: Betaseron - Dose Incrimination Pattern (mg/48 hours), January'2020
  • Figure 20-24: Betaseron - Sales Value (US$/EUR Million), 2017 & 2018
  • Figure 20-25: Betaseron - US v/s ROW Sales Value (%), 2018
  • Figure 20-26: Betaseron - Quarterly Sales Value (US$/EUR Million), 2018
  • Figure 20-27: Betaseron - Quarterly Sales Value (US$/EUR Million), Q1 - Q3, 2019
  • Figure 20-28: Actimmune - FDA Approval & Patent Expiration Year
  • Figure 20-29: Actimmune - Price for 6ml Supply, 1 ml & price for Single Vial of 0.5ml Subcutaneous Solution (US$), January' 2020
  • Figure 20-30: Actimmune - Average Cost of Single Dose & Single Treatment Cycle (US$), January' 2020
  • Figure 20-31: Actimmune - Sales Value (US$/EUR Million), 2017 & 2018
  • Figure 20-32: Actimmune - Quarterly Sales Value (US$/EUR Million), Q1 - Q3, 2019
  • Figure 20-33: Ontack - Duration of Single Treatment Cycle & Full Treatment (Weeks), January' 2020
  • Figure 20-34: Ontack - Average Minimum & Maximum Cost of Single Dose Administration (US$), January' 2020
  • Figure 20-35: Ontack - Average Minimum & Maximum Cost of Single Treatment Cycle (US$), January' 2020
  • Figure 21-1: Imlygic - US & European Patent Expiration Year
  • Figure 21-2: Imlygic - Price of 1 Million PUF/ml & 100 Million PUF/ml Injectable Suspension (US$), January'2020
  • Figure 21-3: Imlygic - Concentration of Dose for Initial Treatment Cycle & Subsequent Treatment Cycle (Million PUF/ml), January'2020
  • Figure 21-4: Imlygic - Average Price of Initial Treatment Cycle & Each Subsequent Treatment Cycle (US$), January'2020
  • Figure 21-5: Imlygic - Volume Administered by Size of Lesion (ml), January'2020
  • Figure 22-1: Kymriah - FDA approval Year by Cancer Type
  • Figure 22-2: Kymriah - Number of Patents in US, Europe & Japan
  • Figure 22-3: Kymriah - Cost of Advanced Lymphoma Treatment (US$ 000'), Janouary'2020
  • Figure 22-4: Kymriah - Cost of Acute Lymphoblastic Leukemia Treatment (US$ 000'), Janouary'2020
  • Figure 22-5: Kymriah - Sales Value (US$ Million), 2017 & 2018
  • Figure 22-6: Kymriah - Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
  • Figure 22-7: Yescarta - FDA Approval & US Patent Expiration Year
  • Figure 22-8: Yescarta - Cost of Advanced Lymphoma Treatment (US$ 000'), Janouary'2020
  • Figure 22-9: Yescarta - Sales Value (US$ Million), 2017 & 2018
  • Figure 22-10: Yescarta - Quarterly Sales Value (US$ Million), Q1-Q3, 2018 & 2019
  • Figure 28-1: Advaxis Clinical Pipeline
  • Figure 28-2: Celldex Therapeutics Clinical Pipeline
  • Figure 28-3: Expression Genetics Clinical Pipeline
  • Figure 28-4: Galena Biopharma Clinical Pipeline
  • Figure 28-5: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 28-6: ImmunoGen Clinical Pipeline
  • Figure 28-7: Inovio Pharmaceuticals Clinical Pipeline
  • Figure 28-8: NewLink Genetics Corporation Clinical Pipeline
  • Figure 28-9: Northwest Biotherapeutics Clinical Pipeline
  • Figure 28-10: Peregrine Pharmaceuticals Clinical Pipeline
  • Figure 28-11: Philogen Clinical Pipeline
  • Figure 28-12: Seattle Genetics Clinical Pipeline

List of Tables

  • Table 5-1: Different Monoclonal Antibodies Used in Cancer Immunotherapy
  • Table 7-1: Illustration of Some Important Checkpoint Inhibitors
  • Table 10-1: Few Important Immunocytokines under Clinical Development
  • Table 10-2: Some Pharmacologically Important Cytokines Used in Cancer Immunotherapies
  • Table 14-1: Few Commercially Important PD-1 Drugs